Cullinan Therapeutics(CGEM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CGEM Cullinan Therapeutics

休市中 12-05 16:00:00 EST

10.59

+0.01

+0.09%

盘后10.75

+0.16+1.51%

18:49 EST

最高10.80	最低10.28	成交量77.83万
今开10.69	昨收10.58	日振幅4.90%
总市值6.26亿	流通市值3.82亿	总股本5,908万
成交额821.60万	换手率2.16%	流通股本3,606万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CGEM","market":"US","secType":"STK","nameCN":"Cullinan Therapeutics","latestPrice":10.59,"timestamp":1764968400000,"preClose":10.58,"halted":0,"volume":778336,"hourTrading":{"tag":"盘后","latestPrice":10.75,"preClose":10.59,"latestTime":"18:49 EST","volume":18233,"amount":193245.5606,"timestamp":1764978584445},"delay":0,"floatShares":36055085,"shares":59076259,"eps":-3.680879,"marketStatus":"休市中","change":0.01,"latestTime":"12-05 16:00:00 EST","open":10.69,"high":10.7989,"low":10.28,"amount":8216030.755712,"amplitude":0.049045,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.680879,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1610082000000,"exchange":"NASDAQ","adjPreClose":10.58,"preHourTrading":{"tag":"盘前","latestPrice":10.63,"preClose":10.58,"latestTime":"09:06 EST","volume":280,"amount":2988.60618,"timestamp":1764943617829},"postHourTrading":{"tag":"盘后","latestPrice":10.75,"preClose":10.59,"latestTime":"18:49 EST","volume":18233,"amount":193245.5606,"timestamp":1764978584445},"volumeRatio":0.7175407374631853,"impliedVol":1.4519,"impliedVolPercentile":0.788},"requestUrl":"/m/hq/s/CGEM","defaultTab":"news","newsList":[{"id":"1198297884","title":"Cullinan Therapeutics获FDA快速通道认证，推出Cln-049治疗复发/难治性急性髓系白血病","url":"https://stock-news.laohu8.com/highlight/detail?id=1198297884","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198297884?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:01","pubTimestamp":1764590474,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics获FDA快速通道认证，推出Cln-049，这是一种新型的Flt3xcd3 T细胞引导剂，旨在治疗复发和难治性的急性髓系白血病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"gpt_icon":0},{"id":"1104008946","title":"Cullinan Therapeutics - Cullinan Amber 通知终止 Cln-617 独占专利许可协议的决定","url":"https://stock-news.laohu8.com/highlight/detail?id=1104008946","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104008946?lang=zh_cn&edition=full","pubTime":"2025-11-22 05:36","pubTimestamp":1763760968,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics - Cullinan Amber 通知终止 Cln-617 独占专利许可协议的决定","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"gpt_icon":0},{"id":"1139722733","title":"Taiho Oncology Inc：预计在2026年第一季度完成NDA提交，并申请优先审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1139722733","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139722733?lang=zh_cn&edition=full","pubTime":"2025-11-20 20:20","pubTimestamp":1763641221,"startTime":"0","endTime":"0","summary":"Taiho Oncology Inc：预计在2026年第一季度完成NDA提交，并申请优先审查","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"gpt_icon":0},{"id":"1150432084","title":"泰豪肿瘤学、泰豪制药和Cullinan Therapeutics启动针对Zipalertinib的新药申请滚动提交，旨在治疗带有EGFR外显子20插入突变的局部晚期或转移性非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1150432084","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150432084?lang=zh_cn&edition=full","pubTime":"2025-11-20 20:19","pubTimestamp":1763641186,"startTime":"0","endTime":"0","summary":"泰豪肿瘤学、泰豪制药和Cullinan Therapeutics启动针对Zipalertinib的新药申请滚动提交，旨在治疗带有EGFR外显子20插入突变的局部晚期或转移性非小细胞肺癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"gpt_icon":0},{"id":"1121722491","title":"Cullinan Therapeutics第三季度运营费用为5559.5万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121722491","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121722491?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:58","pubTimestamp":1763571512,"startTime":"0","endTime":"0","summary":"11月6日 - Cullinan Therapeutics第三季度营业收入为-5559.5万美元，低于IBES预测的-6330万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"gpt_icon":0},{"id":"2542053656","title":"Stifel：重申Cullinan Therapeutics(CGEM.US)买入评级, 目标价22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542053656","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542053656?lang=zh_cn&edition=full","pubTime":"2025-06-11 23:56","pubTimestamp":1749657401,"startTime":"0","endTime":"0","summary":"Stifel：重申Cullinan Therapeutics(CGEM.US)买入评级, 目标价22.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/11235651017338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CGEM","LENZ"],"gpt_icon":0},{"id":"2541079446","title":"Cullinan Therapeutics, Inc.盘中异动 早盘急速跳水5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2541079446","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541079446?lang=zh_cn&edition=full","pubTime":"2025-06-05 22:11","pubTimestamp":1749132695,"startTime":"0","endTime":"0","summary":"北京时间2025年06月05日22时11分，Cullinan Therapeutics, Inc.股票出现波动，股价大幅跳水5.51%。截至发稿，该股报8.57美元/股，成交量4.1426万股，换手率0.07%，振幅3.97%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.35%。其相关个股中，Immatics N V C/Wts 01/07/2025 、Liminatus Pharma Inc C/Wts 30/04/2030 、Scinai Immunotherapeutics Ltd涨幅较大，Scinai Immunotherapeutics Ltd、Nucana Plc、Silo Pharma, Inc.较为活跃，换手率分别为1562.02%、371.20%、166.49%，振幅较大的相关个股有Liminatus Pharma Inc C/Wts 30/04/2030 、Scinai Immunotherapeutics Ltd、Eyenovia, Inc.，振幅分别为137.71%、92.46%、47.48%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605221135a6fbe1c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605221135a6fbe1c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CGEM","BK4007","LENZ","BK4539"],"gpt_icon":0},{"id":"2541811013","title":"总金额超7亿美元！智翔金泰与Cullinan Therapeutics就GR1803注射液达成海外独家授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2541811013","media":"智翔金泰生物","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541811013?lang=zh_cn&edition=full","pubTime":"2025-06-05 08:52","pubTimestamp":1749084777,"startTime":"0","endTime":"0","summary":"6月5日，智翔金泰宣布，与纳斯达克上市公司Cullinan Therapeutics,Inc.达成海外授权合作协议。智翔金泰将保留GR1803注射液在大中华区的开发、生产、商业化权益，并积极推进现有临床适应症的开发及在中国的上市。根据协议条款，Cullinan将向智翔金泰支付2000万美元首付款，以及最高6.92亿美元的开发、监管批准和销售里程碑付款。此外，智翔金泰将获得授权区域净销售额最高中双位数的分级特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605085648a6faee91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605085648a6faee91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4139","BK4539","CGEM"],"gpt_icon":0},{"id":"2518209158","title":"Cullinan Therapeutics, Inc.盘中异动 快速跳水5.17%报8.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518209158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518209158?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:24","pubTimestamp":1741631062,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时24分，Cullinan Therapeutics, Inc.股票出现波动，股价大幅跳水5.17%。截至发稿，该股报8.26美元/股，成交量27.8959万股，换手率0.48%，振幅4.42%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为5992.88%、3846.69%、1004.73%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、59.34%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102242296406faa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102242296406faa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CGEM","LENZ","BK4139"],"gpt_icon":0},{"id":"2517543010","title":"Cullinan Therapeutics, Inc.2024财年实现净利润-1.67亿美元，同比减少9.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517543010","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517543010?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363238,"startTime":"0","endTime":"0","summary":"3月8日，Cullinan Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.67亿美元，同比减少9.15%；其中营业收入为0.00美元，每股基本收益为-3.11美元。从资产负债表来看，Cullinan Therapeutics, Inc.总负债32.10百万美元，其中短期债务1.30百万美元，资产负债比为0.20，流动比率为0.14。机构评级：截至2025年3月8日，当前有9家机构对Cullinan Therapeutics, Inc.目标价做出预测，其中目标均价为32.11美元，其中最低目标价为29.00美元，最高目标价为36.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000048a2647e67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000048a2647e67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CGEM"],"gpt_icon":0},{"id":"2516668196","title":"Cullinan Therapeutics, Inc.盘中异动 急速下跌5.18%报8.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668196","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516668196?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:18","pubTimestamp":1741033097,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时18分，Cullinan Therapeutics, Inc.股票出现波动，股价急速下挫5.18%。截至发稿，该股报8.05美元/股，成交量26.88万股，换手率0.46%，振幅6.54%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4598.52%、213.15%、183.16%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041817989a5cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041817989a5cd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CGEM","BK4139","LENZ"],"gpt_icon":0},{"id":"1198439624","title":"Cullinan Therapeutics 2024年第四季度GAAP每股收益$(0.73)优于预期$(0.76)","url":"https://stock-news.laohu8.com/highlight/detail?id=1198439624","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198439624?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:28","pubTimestamp":1740659337,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics(CGEM)（纳斯达克股票代码：CGEM）报告称季度每股亏损$(0.73)，优于分析师一致预期的$(0.76)，超出3.95%。以上内容来自Benzinga Earnings专栏，原文如下：$Cullinan Therapeutics(CGEM)$ (NASDAQ:CGEM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cullinan Therapeutics 2024年第四季度GAAP每股收益$(0.73)优于预期$(0.76)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"gpt_icon":0},{"id":"2508141755","title":"Cullinan Therapeutics, Inc.盘中异动 大幅跳水5.11%报10.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508141755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508141755?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:46","pubTimestamp":1738593987,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时46分，Cullinan Therapeutics, Inc.股票出现异动，股价快速跳水5.11%。截至发稿，该股报10.02美元/股，成交量6649股，换手率0.01%，振幅2.51%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.41%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Invivyd, Inc.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为413.54%、349.94%、203.60%，振幅较大的相关个股有Hcw Biologics Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Invivyd, Inc.，振幅分别为82.67%、50.76%、35.62%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203224627abc10aef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203224627abc10aef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CGEM","LENZ"],"gpt_icon":0},{"id":"2507518286","title":"HC Wainwright & Co.：维持Cullinan Therapeutics(CGEM.US)评级，由买入调整至买入评级, 目标价由28.00美元调整至33.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507518286","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507518286?lang=zh_cn&edition=full","pubTime":"2025-01-30 02:04","pubTimestamp":1738173876,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Cullinan Therapeutics(CGEM.US)评级，由买入调整至买入评级, 目标价由28.00美元调整至33.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30020447899099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CGEM","LENZ"],"gpt_icon":0},{"id":"2507631524","title":"Cullinan Therapeutics, Inc.盘中异动 早盘急速上涨6.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507631524","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507631524?lang=zh_cn&edition=full","pubTime":"2025-01-29 22:33","pubTimestamp":1738161182,"startTime":"0","endTime":"0","summary":"北京时间2025年01月29日22时33分，Cullinan Therapeutics, Inc.股票出现波动，股价大幅上涨6.03%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Ocean Biomedical Inc C/Wts 14/02/2028 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Ocean Biomedical, Inc.涨幅较大，Silexion Therapeutics Corp、60 Degrees Pharmaceuticals, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为2029.27%、1486.33%、624.87%，振幅较大的相关个股有Ocean Biomedical Inc C/Wts 14/02/2028 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Ocean Biomedical, Inc.，振幅分别为114.29%、50.00%、30.12%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012922330298760a46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012922330298760a46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CGEM"],"gpt_icon":0},{"id":"2492409444","title":"Cullinan Therapeutics, Inc.盘中异动 急速上涨5.48%报11.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492409444","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492409444?lang=zh_cn&edition=full","pubTime":"2024-12-20 22:38","pubTimestamp":1734705495,"startTime":"0","endTime":"0","summary":"北京时间2024年12月20日22时38分，Cullinan Therapeutics, Inc.股票出现波动，股价急速拉升5.48%。截至发稿，该股报11.55美元/股，成交量7.71万股，换手率0.13%，振幅6.12%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。其相关个股中，Humacyte Inc C/Wts 27/08/2026 、Humacyte, Inc.、Psyence Biomedical Ltd.涨幅较大，Psyence Biomedical Ltd.、Aptose Biosciences, Inc.、Aditxt, Inc.较为活跃，换手率分别为1824.56%、82.42%、55.31%，振幅较大的相关个股有Humacyte, Inc.、Humacyte Inc C/Wts 27/08/2026 、Quoin Pharmaceuticals Ltd，振幅分别为35.26%、34.80%、30.92%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220223815984cfc5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220223815984cfc5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CGEM","LENZ"],"gpt_icon":0},{"id":"2486588356","title":"Cullinan Therapeutics, Inc.盘中异动 急速拉升5.14%报13.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486588356","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486588356?lang=zh_cn&edition=full","pubTime":"2024-11-27 00:03","pubTimestamp":1732636993,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日00时03分，Cullinan Therapeutics, Inc.股票出现波动，股价急速拉升5.14%。截至发稿，该股报13.19美元/股，成交量12.0849万股，换手率0.21%，振幅4.47%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.22%。其相关个股中，Poseida Therapeutics, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 、Ventyx Biosciences, Inc.涨幅较大，Elevai Labs, Inc.、木薯科学、Poseida Therapeutics, Inc.较为活跃，换手率分别为38.16%、25.56%、21.93%，振幅较大的相关个股有Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Tc Biopharm  Plc C/Wts 10/02/2028 、Protagenic Therapeutics, Inc.，振幅分别为85.82%、50.00%、42.94%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112700031398e44b6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112700031398e44b6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CGEM","BK4139"],"gpt_icon":0},{"id":"2484385988","title":"Cullinan Therapeutics, Inc.盘中异动 股价大跌5.19%报13.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484385988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484385988?lang=zh_cn&edition=full","pubTime":"2024-11-19 03:23","pubTimestamp":1731957785,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日03时23分，Cullinan Therapeutics, Inc.股票出现异动，股价急速下跌5.19%。截至发稿，该股报13.14美元/股，成交量26.9188万股，换手率0.46%，振幅6.31%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Hcw Biologics Inc.、冠科美博、Apollomics Inc C/Wts 01/04/2028 涨幅较大，冠科美博、Hcw Biologics Inc.、Tharimmune, Inc.较为活跃，换手率分别为1399.01%、1260.16%、569.88%，振幅较大的相关个股有Hcw Biologics Inc.、冠科美博、Apollomics Inc C/Wts 01/04/2028 ，振幅分别为563.48%、221.58%、193.44%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119032306a243a5ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119032306a243a5ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CGEM","BK4139"],"gpt_icon":0},{"id":"2481102978","title":"Cullinan Therapeutics, Inc.盘中异动 急速上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481102978","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481102978?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:46","pubTimestamp":1731077177,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日22时46分，Cullinan Therapeutics, Inc.股票出现异动，股价快速上涨5.01%。截至发稿，该股报16.36美元/股，成交量4.1812万股，换手率0.07%，振幅3.34%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Fortrea Holdings Inc.、Lipella Pharmaceuticals Inc.、Matinas Biopharma Holdings, Inc.涨幅较大，Elevai Labs, Inc.、Matinas Biopharma Holdings, Inc.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为462.02%、39.55%、23.24%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Lipella Pharmaceuticals Inc.，振幅分别为86.00%、31.72%、29.95%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822461798e417d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822461798e417d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CGEM","BK4139"],"gpt_icon":0},{"id":"2475683560","title":"Cullinan Therapeutics, Inc.盘中异动 股价大涨5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475683560","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475683560?lang=zh_cn&edition=full","pubTime":"2024-10-15 21:31","pubTimestamp":1728999078,"startTime":"0","endTime":"0","summary":"北京时间2024年10月15日21时31分，Cullinan Therapeutics, Inc.股票出现波动，股价快速上涨5.98%。截至发稿，该股报17.20美元/股，成交量2250股，换手率0.00%，振幅1.11%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.11%。其相关个股中，Apollomics Inc C/Wts 01/04/2028 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Lipella Pharmaceuticals Inc.、Enveric Biosciences, Inc.、Gritstone Bio, Inc.较为活跃，换手率分别为238.21%、163.82%、125.12%，振幅较大的相关个股有Notable Labs, Ltd.、Bright Minds Biosciences Inc.、Genprex, Inc.，振幅分别为12.25%、10.04%、7.99%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101521311898e3c860&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101521311898e3c860&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CGEM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cullinantherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0686},{"period":"1month","weight":0.4487},{"period":"3month","weight":0.515},{"period":"6month","weight":0.1663},{"period":"1year","weight":-0.1487},{"period":"ytd","weight":-0.1305}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cullinan Therapeutics, Inc.于特拉华州注册成立。该公司是一家生物制药公司，专注于为癌症患者开发具有转化潜力的肿瘤靶向治疗和免疫肿瘤治疗的多样化渠道。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.082426},{"month":2,"riseRate":0.6,"avgChangeRate":0.024211},{"month":3,"riseRate":0.2,"avgChangeRate":-0.103725},{"month":4,"riseRate":0.4,"avgChangeRate":0.06919},{"month":5,"riseRate":0.6,"avgChangeRate":-0.004749},{"month":6,"riseRate":0.4,"avgChangeRate":-0.054955},{"month":7,"riseRate":0.6,"avgChangeRate":0.01398},{"month":8,"riseRate":0.4,"avgChangeRate":0.037827},{"month":9,"riseRate":0,"avgChangeRate":-0.146845},{"month":10,"riseRate":0.6,"avgChangeRate":0.085935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.037651},{"month":12,"riseRate":0.2,"avgChangeRate":-0.04257}],"exchange":"NASDAQ","name":"Cullinan Therapeutics","nameEN":"Cullinan Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cullinan Therapeutics(CGEM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cullinan Therapeutics(CGEM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cullinan Therapeutics,CGEM,Cullinan Therapeutics股票,Cullinan Therapeutics股票老虎,Cullinan Therapeutics股票老虎国际,Cullinan Therapeutics行情,Cullinan Therapeutics股票行情,Cullinan Therapeutics股价,Cullinan Therapeutics股市,Cullinan Therapeutics股票价格,Cullinan Therapeutics股票交易,Cullinan Therapeutics股票购买,Cullinan Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cullinan Therapeutics(CGEM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cullinan Therapeutics(CGEM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}